 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for February 16, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| CEL | Hot Stocks15:27 EST Cellcom Israel announces negotiations to purchase Golan Telecom - Cellcom Israel announced that it is in negotiations with Golan Telecom's, or Golan Telecom, shareholders, in regards to possible purchase of its holdings in Golan Telecom. The company added that it cannot guarantee that such discussions will mature into a transaction.
|
| BMY | Hot Stocks15:25 EST Bristol-Myers announced five-year follow-up results from Phase 3 CheckMate -025 - Bristol-Myers Squibb announced five-year follow-up results from the Phase 3 CheckMate -025 study, which continue to demonstrate that treatment with Opdivo delivers superior overall survival and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma compared to those treated with everolimus. With an extended minimum follow-up of 64 months, patients treated with Opdivo continue to demonstrate OS benefit with 26% of patients alive compared to 18% of patients treated with everolimus. Additionally, the percentage of patients experiencing an objective response was 23% for Opdivo versus 4% for everolimus and the median duration of response for Opdivo was also maintained longer than for everolimus. The overall safety profile was consistent with that observed in previously reported analyses from CheckMate -025 in patients with RCC. No new safety signals or drug-related deaths occurred with extended follow-up.
|
| BMY | Hot Stocks15:23 EST Bristol-Myers announced updated results from Phase 3 CheckMate -214 study - Bristol-Myers Squibb announced updated results from the Phase 3 CheckMate -214 study evaluating the combination of Opdivo plus Yervoy versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma. With a minimum follow-up of 42 months, the combination of Opdivo plus Yervoy continues to show superior overall survival, objective response rates, duration of response and complete response rates. The safety profile for Opdivo plus Yervoy was consistent with prior findings and no new safety signals or drug-related deaths occurred with extended follow-up. A significant OS benefit was observed in both patients from the intermediate- and poor-risk and the intent-to-treat populations treated with Opdivo plus Yervoy compared to those treated with sunitinib alone. Of the patients treated with Opdivo plus Yervoy who experienced a complete response, per independent review, that response was ongoing in 84% and 86% of patients in the IP and ITT populations, respectively.
|
| BMY MRTX | Hot Stocks08:45 EST Mirati Therapeutics announces trial initial data in Renal Cell Carcinoma - Mirati Therapeutics (MRTX) announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with Bristol-Myers' (BMY) nivolumab in patients with advanced clear cell renal cell cancer who have documented progression on a prior VEGF-targeted therapy. As of the data cut-off date of January 1, 2020, 38 out of 40 patients enrolled were evaluable for response at greater than 12 weeks on therapy. 15/38 patients achieved a confirmed partial response including one PR that has improved to an unconfirmed complete response. 35/38 patients achieved clinical benefit. Initial median progression-free survival was 10.3 months. Median overall survival has not yet been reached with 30/38 patients still on study as of the data cut-off date. The combination has been well-tolerated with manageable adverse events.
|
